Journal article
Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration
F Abedi, S Wickremasinghe, AJ Richardson, E Makalic, DF Schmidt, SS Sandhu, PN Baird, RH Guymer
Ophthalmology | ELSEVIER SCIENCE INC | Published : 2013
Abstract
Purpose: To determine the association of genetic variants of the VEGFA gene with outcome of anti-vascular endothelial growth factor (VEGF) treatment in neovascular age-related macular degeneration (AMD). Design: A prospective cohort study. Participants: We included 201 consecutive patients receiving anti-VEGF injections for neovascular AMD. Methods: Patients were followed over 12 months. They were treated with 3 initial monthly ranibizumab or bevacizumab injections. Thereafter, the decision to retreat was made by clinicians at each follow-up visit on the basis of retreatment criteria. Seven tagged single nucleotide polymorphisms (tSNPs) in the VEGFA gene were selected and examined. Multivari..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This project was partly funded by the National Health and Medical Research Council (NHMRC) project grants 590205 and 1008979, an NHMRC-Clinical Research Excellence grant 529923, NHMRC practitioner fellowship (R. H. G.), NHMRC Research Fellowship (P.N.B.), and the Macular Vision Loss Support Society of Australia. The Centre for Eye Research Australia (CERA) receives Operational Infrastructure Support from the Victorian Government. The sponsor or funding organizations had no role in the design or conduct of this research.